文献速递MDS 与骨髓增殖性肿瘤

TRANSFORM-1 III期研究:navitoclax联合ruxolitinib治疗初治骨髓纤维化的疗效与安全性

TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
PubMed 文献 · Blood · 2026-01-01

TRANSFORM-1是一项III期随机研究,在252例未接受JAK抑制剂治疗的中危-2或高危骨髓纤维化患者中比较navitoclax联合ruxolitinib与安慰剂联合ruxolitinib。联合组血液学毒性更高,但细胞减少一般可通过剂量调整管理且可逆。

要点

  • NAV+RUX组3/4级血小板减少54.0%、中性粒细胞减少40.3%,高于对照组。

核心结论

  • 在未接受JAK抑制剂治疗的中危-2或高危骨髓纤维化患者中,navitoclax联合ruxolitinib较安慰剂联合ruxolitinib显著提高第24周SVR35率。

研究设计与样本

  • III期TRANSFORM-1研究随机纳入252例未接受JAK抑制剂治疗的中危-2或高危骨髓纤维化成人患者,ECOG体能状态≤2。
  • 患者按1:1随机接受navitoclax(起始200 mg/d,或100 mg递增至200 mg/d)或安慰剂,联合按说明书给药的ruxolitinib。
  • NAV+RUX组125例,PBO+RUX组127例,中位随访20.3个月。

主要发现

  • 探索性终点等位基因频率降低≥20%在NAV+RUX组为58.5%(95%CI 49.0-67.5),PBO+RUX组为45.5%(95%CI 36.4-54.8)。
  • NAV+RUX组3/4级血小板减少54.0% vs 19.2%,3/4级中性粒细胞减少40.3% vs 8.8%,任意级别腹泻41.9% vs 16.8%。

关键数值与推荐

  • 主要终点为第24周脾体积缩小≥35%(SVR35W24)。
  • NAV+RUX组3/4级血小板减少54.0%、3/4级中性粒细胞减少40.3%,PBO+RUX组分别为19.2%和8.8%。

临床怎么用

  • 对于未接受JAK抑制剂治疗的中危-2或高危骨髓纤维化患者,navitoclax联合ruxolitinib可显著提高第24周脾体积缩小达标率。
  • 联合方案血液学毒性较高,治疗中需监测血细胞计数,细胞减少一般可通过剂量调整管理且可逆。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 TRANSFORM-1 study evaluated ruxolitinib (RUX) in combination with navitoclax (NAV) or placebo (PBO) in Janus kinase inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis and Eastern Cooperative Oncology Group performance status of ≤2. Patients were randomized 1:1 to NAV (200 mg/d starting dose, or 100 mg escalated to 200 mg/d) or PBO, with RUX dosed per label. The primary end point was ≥35% spleen volume reduction (SVR) at week 24 (SVR35W24). Secondary end points included change from baseline in total symptom score (TSS) at week 24 and SVR35 at any time. A total of 252 patients (NAV+RUX, n = 125; PBO+RUX, n = 127; median follow-up 20.3 months) were randomized; >80% had intermediate-2 risk, and ∼50% had high-molecular risk disease. SVR35W24 was achieved by 63.2% with NAV+RUX vs 31.5% with PBO+RUX (P< .0001). Mean change in TSS at week 24 was not significantly different between NAV+RUX and PBO+RUX (-10.2 vs -11.6; P = .2852). SVR35 at any time was achieved in 76.8% with NAV+RUX vs 44.1% with PBO+RUX (nominal P< .0001). A ≥20% variant allele frequency reduction (exploratory end point) occurred in 58.5% (95% confidence interval [CI], 49.0-67.5) with NAV+RUX and 45.5% (95% CI, 36.4-54.8) with PBO+RUX. NAV+RUX showed higher hematologic toxicity vs PBO+RUX (grade 3/4 thrombocytopenia, 54.0% vs 19.2%; grade 3/4 neutropenia, 40.3% vs 8.8%); diarrhea (any grade, 41.9% vs 16.8%) was also more common. Cytopenias were generally manageable and reversible with dose adjustments. This trial was registered at www.clinicaltrials.gov as NCT04472598.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pemmaraju N, Mead AJ, Somervaille TCP, et al. TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Blood. 2026. PMID: 42378247. doi:10.1182/blood.2025032360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。